<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998971</url>
  </required_header>
  <id_info>
    <org_study_id>CR103015</org_study_id>
    <secondary_id>54767414MMY1001</secondary_id>
    <secondary_id>2013-003491-12</secondary_id>
    <nct_id>NCT01998971</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and dose regimen of
      daratumumab when administered in combination with various backbone treatments for the
      treatment of multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known) study to evaluate the
      safety, tolerability, and dose of daratumumab when administered in combination with various
      backbone treatments for different settings of multiple myeloma. The backbone treatments to
      be combined with daratumumab in this study include Velcade-dexamethasone,
      Velcade-melphalan-prednisone, Velcade-thalidomide-dexamethasone, and
      pomalidomide-dexamethasone. Approximately 48 patients (12 per backbone treatment) will be
      enrolled in this study. The study will consist of screening, treatment, and follow-up
      phases. Treatment will extend to either the planned treatment duration for a maximum of 1
      year, or until disease progression. Follow-up will continue until the study ends
      (approximately 15 months after the last patient receives the first dose of daratumumab).
      Serial pharmacokinetic (study of what a drug does to the body) blood samples will be
      collected. Clinical efficacy outcomes and safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants affected by dose-limiting toxicities</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration of daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with generation of antibodies to daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-dexamethasone (VD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Administered by intravenous infusion in combination with the applicable backbone treatment.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Administered subcutaneously in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Administered in prophylactic doses by mouth in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease

          -  Eastern Cooperative Oncology Group performance status score of 0, 1, or 2

          -  Pretreatment clinical laboratory values must meet protocol-defined parameters during
             the screening phase

        Exclusion Criteria:

          -  Previously received daratumumab or other anti-CD38 therapies

          -  Diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance,
             smoldering multiple myeloma, Waldenström's disease, or other conditions in which IgM
             M-protein is present in the absence of a clonal plasma cell infiltration with lytic
             bone lesions

          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher

          -  Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years
             of study start

          -  Exhibiting clinical signs of meningeal involvement of multiple myeloma

          -  Known chronic obstructive pulmonary disease, persistent asthma, or a history of
             asthma within 5 years

          -  Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C

          -  Any concurrent medical or psychiatric condition or disease that is likely to
             interfere with the study procedures or results, or that in the opinion of the
             investigator, would constitute a hazard for participating in this study

          -  Clinically significant cardiac disease

          -  Plasma cell leukemia or POEMS (polyneuropathy, organomegaly, endocrinopathy,
             monoclonal protein, and skin changes) syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR103015</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>JNJ-54767414</keyword>
  <keyword>Velcade-dexamethasone</keyword>
  <keyword>Velcade-melphalan-prednisone</keyword>
  <keyword>Velcade-thalidomide-dexamethasone</keyword>
  <keyword>Pomalidomide-dexamethasone</keyword>
  <keyword>Anti-CD38 Monoclonal Antibody</keyword>
  <keyword>Immunomodulatory drug</keyword>
  <keyword>IMiD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
